

(FILE 'HOME' ENTERED AT 17:47:01 ON 09 MAY 2001)

FILE 'REGISTRY' ENTERED AT 17:47:18 ON 09 MAY 2001

L1 32 S ILLKVAG/SQSP

L2 1 S ILLKVAG/SQEP

FILE 'CAPLUS' ENTERED AT 17:47:47 ON 09 MAY 2001

L3 2 S L2

L4 28 S L1

FILE 'REGISTRY' ENTERED AT 17:52:06 ON 09 MAY 2001

L5 1 S 94219-00-8

L6 2 S L1 AND SQL<11

FILE 'CAPLUS, TOXLIT' ENTERED AT 17:52:44 ON 09 MAY 2001

L7 3 S L6

L8 2 DUP REM L7 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 17:53:12 ON 09 MAY 2001

L9 1 S LRILLGV/SQEP

L10 1 S LGILLKV/SQEP

L11 1 S ILLGKATLY/SQEP

L12 1 S MGLRILL/SQEP

L13 1 S LLMTLRWSS/SQEP

FILE 'CAPLUS, TOXLIT, USPATFULL' ENTERED AT 17:55:34 ON 09 MAY 2001

L14 6 S L9-L13

L15 5 DUP REM L14 (1 DUPLICATE REMOVED)

FILE 'REGISTRY' ENTERED AT 17:58:23 ON 09 MAY 2001

L16 1 S IIVTDVIATL/SQEP

L17 1 S IVIVDIT/SQEP

L18 1 S FLFAEIVSI/SQEP

L19 1 S AGFNLLMT/SQEP

L20 1 S YGRADCGITS/SQEP

L21 1 S YGRADCGITS/SQSP

L22 1 S WGRADCGITS/SQEP

L23 1 S YGRADCITS/SQEP

L24 1 S SSDVPCDATLT/SQEP

FILE 'CAPLUS, TOXLIT, USPATFULL' ENTERED AT 18:00:43 ON 09 MAY 2001

L25 1 S L16-L24

FILE 'REGISTRY' ENTERED AT 18:02:25 ON 09 MAY 2001

L26 0 S (LVIMFYW){2-10}[KHR]/SQSP

L27 162289 S [LVIMFYW][LVIMFYW][KHR][LVIMFYW][LVIMFYW]/SQSP

L28 0 S L27AND SQL=5

L29 53693 S [LVIMFYW][LVIMFYW][LVIMFYW][KHR][LVIMFYW][LVIMFYW]/SQSP

L30 53693 S [LVIMFYW][LVIMFYW][LVIMFYW][KHR][LVIMFYW][LVIMFYW]/SQSP

L31 22 S L30 AND SQL=6

FILE 'CAPLUS, USPATFULL' ENTERED AT 18:07:15 ON 09 MAY 2001

L32 65 S L31

L33 58 DUP REM L32 (7 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 18:08:38 ON 09 MAY 2001

L34 52766 S [LVIMFYW][LVIMFYW][LVIMFYW][ED][LVIMFYW][LVIMFYW]/SQSP

L35 22 S L34 AND SQL=6


FILE 'CAPLUS, USPATFULL' ENTERED AT 18:09:28 ON 09 MAY 2001
L36 14 S L35
L37 14 DUP REM L36 (0 DUPLICATES REMOVED)

FILE 'REGISTRY' ENTERED AT 18:11:44 ON 09 MAY 2001
L38 0 S 107041-06-5/SQIDE

L40 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2001 ACS
 AN 1987:100588 CAPLUS
 DN 106:100588
 TI Inhibition of phosphorylcholine binding to antibodies using synthetic peptides
 AU Lai, Eric H. C.; Kabat, Elvin A.; Meienhofer, Johannes; Heimer, E. P.; Olson, Arthur J.; Lerner, Richard
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Nature (London) (1987), 325(7000), 168-71
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English
 CC 15-3 (Immunochemistry)
 AB The amino-acid sequence Phe-Tyr-Met-Glu is unique to phosphorylcholine (PC)-binding antibodies. This unique tetrapeptide seems to be involved in PC binding. The effectiveness of Phe-Tyr-Met-Glu and other structurally related peptides in inhibiting the binding of PC to PC-binding proteins McPC603 and HOPC8 was compared. Also, a surface-simulation peptide that was constructed to mimic the combining site of McPC603 was tested. Apparently, all these peptides inhibit the binding of PC to PC-binding proteins non-specifically. It was shown by computer modeling that the surface-simulation peptide does not duplicate the combining site of McPC603.
 ST phosphorylcholine peptide antibody binding
 IT Process simulation, biological
 (of phosphorylcholine-binding protein binding to surface-simulation peptide)
 IT Peptides, biological studies
 RL: BIOL (Biological study)
 (phosphorylcholine binding to antibodies inhibition by)
 IT Antibodies
 RL: BIOL (Biological study)
 (phosphorylcholine binding to, inhibition of, by synthetic peptides)
 IT Proteins, specific or class
 RL: BIOL (Biological study)
 (phosphorylcholine-binding, Igs, peptide inhibition of binding by)
 IT 107-73-3, Phosphorylcholine
 RL: BIOL (Biological study)
 (antibodies binding to, inhibition of, by synthetic peptides)
 IT 62-49-7 563-24-6, Glycerol phosphorylcholine 58569-55-4, Met-enkephalin 58822-25-6 69871-75-6 79942-99-7 89755-21-5 107041-02-1 107041-03-2 107041-04-3 107041-05-4 **107041-06-5** 107041-07-6
 RL: BIOL (Biological study)

L37 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 2000:455708 CAPLUS
 DN 133:187583
 TI Structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from the sequence of an endothelin antagonist
 AU Yahalom, Dror; Rahimipour, Shai; Koch, Yitzhak; Ben-Aroya, Nurit; Fridkin, Mati
 CS Departments of Organic Chemistry and Neurobiology, Weizmann Institute of Science, Rehovot, 76100, Israel
 SO J. Med. Chem. (2000), 43(15), 2824-2830
 CODEN: JMCMAR; ISSN: 0022-2623
 PB American Chemical Society
 DT Journal
 LA English
 IT **289653-43-6**
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (structure-activity studies of reduced-size gonadotropin-releasing hormone agonists derived from sequence of endothelin antagonist)
 RN 289653-43-6 CAPLUS
 CN
 Cyclo(L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophyl-D-tryptophyl-L-leucyl) (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 22

RE


- (2) Bernatowicz, M; Anal Biochem 1986, V155, P95 CAPLUS
 - (3) Burgus, R; Proc Natl Acad Sci U S A 1972, V69, P278 CAPLUS
 - (4) Cody, W; J Med Chem 1995, V38, P2809 CAPLUS
 - (5) Daane, T; Endocrinology 1971, V88, P653 CAPLUS
 - (6) Doherty, A; J Med Chem 1993, V36, P2585 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2001 ACS


AN 2001:8549 CAPLUS
 DN 134:208114
 TI Synthesis of N-4909 analogs Part I. A stimulant of apolipoprotein E secretion in human hepatoma G2 cells
 AU Yanai, Makoto; Suzuki, Masashi; Kawamura, Kouji; Oshida, Norio; Hiramoto, Shigeru; Yasuda, Ori; Shingai, Akiko; Suguro, Toshio
 CS 1st Pharmaceutical Laboratory, Pharmaceutical Research Laboratories, Nisshin Flour Milling Co., Ltd., Saitama, 356-8511, Japan
 SO J. Antibiot. (2000), 53(12), 1385-1396
 CODEN: JANTAJ; ISSN: 0021-8820
 PB Japan Antibiotics Research Association
 DT Journal
 LA English
 IT 201039-90-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. of N-4909 analogs as stimulants of apolipoprotein E secretion in human hepatoma G2 cells)
 RN 201039-90-9 CAPLUS
 CN L-Isoleucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucyl-D-leucyl-L-valyl-L-.alpha.-aspartyl-D-leucyl-, 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RE.CNT 6


RE

- (1) Hiramoto, S; J Antibiotics 1996, V49, P949 CAPLUS
- (2) Mahley, R; J Clin Invest 1989, V83, P2125 CAPLUS

(3) Suguro, T; J Antibiotics 1999, V52, P835 CAPLUS
(4) Yamada, N; J Clin Invest 1992, V89, P706 CAPLUS
(5) Yamada, N; Proc Natl Acad Sci 1989, V86, P665 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2001 ACS
AN 2000:187698 CAPLUS
DN 132:317436
TI Chromatographic resolution of tryptophan enantiomers with
L-Leu-L-Leu-L-Leu peptide. Effects of mobile phase composition and
chromatographic support
AU Kaufman, D. B.; Hayes, T.; Buettner, J.; Hammond, D. J.; Carbonell, R. G.
CS Department of Chemical Engineering, North Carolina State University,
Raleigh, NC, USA
SO J. Chromatogr., A (2000), 874(1), 21-26
CODEN: JCRAEY; ISSN: 0021-9673
PB Elsevier Science B.V.
DT Journal
LA English
IT **265112-93-4D**, reaction product with polystyrene
RL: ARU (Analytical role, unclassified); NUU (Nonbiological use,
unclassified); PRP (Properties); ANST (Analytical study); USES (Uses)
(effects of mobile phase compn. and leucine peptide contg. chromatog.
support on chromatog. resoln. of tryptophan enantiomers)
RN 265112-93-4 CAPLUS
CN L-Leucine, L-leucyl-L-leucyl-L-leucyl-L-.alpha.-glutamyl-L-leucyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RE.CNT 10

RE

(1) Baczuk, R; J Chromatogr 1971, V60, P351 CAPLUS
(2) Buettner, J; Int J Peptide Protein Res 1996, V47, P70 CAPLUS
(4) Ihara, T; J Chromatogr A 1995, V694, P49 CAPLUS
(5) Knox, J; J Chromatogr 1981, V218, P341 CAPLUS
(6) Knox, J; J Chromatogr 1982, V234, P222 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L37 ANSWER 4 OF 14 USPATFULL
AN 1999:33978 USPATFULL
TI Cyclic endothelin antagonists
IN Wakimasu, Mitsuhiro, Ibaraki, Japan

Kikuchi, Takashi, Ibaraki, Japan
 Kawada, Akira, Ibaraki, Japan
 Shirafuji, Hideo, Kyoto, Japan
 PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)
 PI US 5883075 19990316
 AI US 1996-680534 19960709 (8)
 RLI Division of Ser. No. US 1994-231449, filed on 20 Apr 1994, now patented,
 Pat. No. US 5616684 which is a continuation of Ser. No. US 1992-927205, filed on 7 Aug 1992, now abandoned
 PRAI JP 1991-203032 19910813
 JP 1991-303635 19911119
 JP 1992-35435 19920221
 JP 1992-111792 19920430
 DT Utility
 EXNAM Primary Examiner: Achutamurthy, Ponnathapura; Assistant Examiner: Wessendorf, T. D.
 LREP Conlin, David G.; Neuner, George W.; Lowen, Cara Z.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1,12
 DRWN No Drawings
 LN.CNT 4813
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT **150209-99-7P**
 (prepn. of, as endothelin and neurokinin antagonist)
 RN 150209-99-7 USPATFULL
 CN Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)




L37 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1998:42417 CAPLUS
 DN 128:102397
 TI Preparation of cyclic depsipeptides as apolipoprotein E production promoters
 IN Yanai, Makoto; Suzuki, Masashi; Oshida, Norio; Kawamura, Koji; Hiramoto, Shigeru; Yasuda, Orie; Kinoshita, Nobuhiro; Shingai, Akiko; Kanai, Masako
 PA Nisshin Flour Milling Co., Ltd., Japan; Yanai, Makoto; Suzuki, Masashi; Oshida, Norio; Kawamura, Koji; Hiramoto, Shigeru; Yasuda, Orie; Kinoshita, Nobuhiro; Shingai, Akiko; Kanai, Masako
 SO PCT Int. Appl., 160 pp.
 CODEN: PIXXD2
 DT Patent
 LA Japanese
 FAN.CNT 1
 PATENT NO. KIND DATE APPLICATION NO. DATE


PI	WO 9749724	Al	19971231	WO 1997-JP2194	19970625
	W: CA, JP, KR, US				
	RW: CH, DE, FR, GB, IT, NL				
	CA 2258487	AA	19971231	CA 1997-2258487	19970625
	EP 967222	Al	19991229	EP 1997-928461	19970625
	R: CH, DE, FR, GB, IT, LI, NL				
PRAI	JP 1996-164317		19960625		
	JP 1996-271321		19960924		
	WO 1997-JP2194		19970625		
OS	MARPAT 128:102397				
IT	201039-90-9P 201040-29-1P 201040-48-4P				
	RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)				
	(prepn. of cyclic depsipeptides as apolipoprotein E and A1 prodn. promoters for treatment of dementia and hyperlipemia)				
RN	201039-90-9 CAPLUS				
CN	L-Isoleucine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-L-leucyl-D-leucyl-L-valyl-L-.alpha.-aspartyl-D-leucyl-, 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 201040-29-1 CAPLUS
 CN L-Isoleucine, L-leucyl-L-leucyl-L-valyl-L-.alpha.-aspartyl-D-leucyl-,
 4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester
 (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 201040-48-4 CAPLUS

CN L-Isoleucine, L-leucyl-L-leucyl-L-valyl-L-.alpha.-aspartyl-L-leucyl-,
4-(1,1-dimethylethyl) 6-[1-[2-oxo-2-(phenylmethoxy)ethyl]dodecyl] ester
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



L37 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 1997:805891 CAPLUS

DN 128:57436

TI A method for selecting target pathogen-inhibiting substances, and test kits for use therein

IN Lankinen, Hilikka; Heiskanen, Tuomas; Vaheri, Antti; Lundkvist, Ake

PA Helsinki University Licensing Ltd., Finland; Lankinen, Hilikka; Heiskanen, Tuomas; Vaheri, Antti; Lundkvist, Ake

SO PCT Int. Appl., 80 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9745743	A1	19971204	WO 1997-FI339	19970530
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB,				

GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN,
ML, MR, NE, SN, TD, TG

FI 9602269	A	19971201	FI 1996-2269	19960530
AU 9729650	A1	19980105	AU 1997-29650	19970530

PRAI FI 1996-2269 19960530
WO 1997-FI339 19970530


IT **200351-45-7**
RL: BAC (Biological activity or effector, except adverse); THU
(Therapeutic use); BIOL (Biological study); USES (Uses)
(method for selecting target pathogen-inhibiting substances, and test
kits)

RN 200351-45-7 CAPLUS


CN L-Tryptophan, L-tryptophyl-L-tyrosyl-L-phenylalanyl-L-.alpha.-aspartyl-L-
valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



L37 ANSWER 7 OF 14 USPATFULL

AN 97:27269 USPATFULL

TI Cyclic peptides and use thereof

IN Wakimasu, Mitsuhiro, Ibaraki, Japan
Kikuchi, Takashi, Ibaraki, Japan
Kawada, Akira, Ibaraki, Japan
Shirafuji, Hideo, Kyoto, Japan

PA Takeda Chemical Industries, Ltd., Osaka, Japan (non-U.S. corporation)


PI US 5616684 19970401

AI US 1994-231449 19940420 (8)


RLI Continuation of Ser. No. US 1992-927205, filed on 7 Aug 1992, now
abandoned

PRAI JP 1991-203032 19910813
JP 1991-303635 19911119
JP 1992-35436 19920221

JP 1992-111792 19920430
 DT Utility
 EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Wessendorf, T.
 D.
 LREP Conlin, David G.; Neuner, George W.; Lowen, Cara Z.
 CLMN Number of Claims: 1
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 4778
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT 150209-99-7P
 (prepn. of, as endothelin and neurokinin antagonist)
 RN 150209-99-7 USPATFULL
 CN Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)




L37 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1995:665446 CAPLUS
 DN 123:75073
 TI Structure-activity relationships of the potent combined endothelinA/endothelinB receptor antagonist Ac-DDipl6-Leu-Asp-Ile-Ile-Trp21 (PD 142893): development of endothelinB receptor selective antagonists
 AU Cody, Wayne L.; He, John X.; DePue, Patricia L.; Waite, Lisa A.; Leonard, Daniele M.; Sefler, Andrea M.; Kaltenbronn, James S.; Haleen, Stephen J.; Walker, Donnelle M.; et al.
 CS Parke-Davis Pharmaceutical Research Division, Warner-Lambert Company, Ann Arbor, MI, 48105, USA
 SO J. Med. Chem. (1995), 38(15), 2809-19
 CODEN: JMCMAR; ISSN: 0022-2623
 DT Journal
 LA English
 IT 165329-39-5 165329-40-8
 RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
 (structure-activity relationships of the potent combined ETA/ETB receptor antagonist PD 142893)
 RN 165329-39-5 CAPLUS
 CN Cyclo(L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophyl-D-phenylalanyl-L-leucyl) (9CI) (CA INDEX NAME)



RN 165329-40-8 CAPLUS

CN Cyclo(L-.alpha.-aspartyl-L-isoleucyl-L-isoleucyl-L-tryptophyl-.beta.-phenyl-D-phenylalanyl-L-leucyl) (9CI) (CA INDEX NAME)



L37 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 1995:624467 CAPLUS

DN 123:329232

TI A new endothelin antagonist lipopeptide isolated from the strain of *Bacillus subtilis*

AU Ohshima, Takeshi; Tamura, Masahiro; Oda, Toshiaki; Hirata, Mitsuteru; Shiratsuchi, Masami; Hamada, Masa; Maeda, Kenji; Takeuchi, Tomio

CS Tokyo Research Laboratories, Kowa Co., Ltd., Higashimurayama, 189, Japan

SO Pept. Chem. (1995), Volume Date 1994, 32nd, 33-6

CODEN: PECHDP; ISSN: 0388-3698

DT Journal

LA English


IT **166034-90-8**


RL: BAC (Biological activity or effector, except adverse); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (new endothelin antagonist lipopeptide isolated from the strain of *Bacillus subtilis* in relation to structure-activity relations of synthetic peptides)

RN 166034-90-8 CAPLUS

CN L-Isoleucine, N-[N-[N-[N-(N-acetyl-L-leucyl)-D-leucyl]-L-valyl]-L-.alpha.-aspartyl]-D-leucyl-, 1-tetradecyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L37 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2001 ACS

AN 1993:603860 CAPLUS

DN 119:203860

TI Preparation of cyclic peptides as endothelin and neurokinin antagonists

IN Wakimasu, Mitsuhiro; Kikuchi, Takashi; Kawada, Akira; Shirahuji, Hideo

PA Takeda Chemical Industries, Ltd., Japan

SO Eur. Pat. Appl., 88 pp.


CODEN: EPXXDW

DT Patent

LA English


FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 528312	A2	19930224	EP 1992-113568	19920808
	EP 528312	A3	19930414		
	EP 528312	B1	19970716		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	AT 155486	E	19970815	AT 1992-113568	19920808
	ES 2103857	T3	19971001	ES 1992-113568	19920808
	CA 2075878	AA	19930214	CA 1992-2075878	19920812
	NO 9203142	A	19930215	NO 1992-3142	19920812
	US 5616684	A	19970401	US 1994-231449	19940420
	JP 08225595	A2	19960903	JP 1995-342625	19951228
	JP 2726647	B2	19980311		
	US 5883075	A	19990316	US 1996-680534	19960709
PRAI	JP 1991-203032		19910813		
	JP 1991-303635		19911119		
	JP 1992-35436		19920221		
	JP 1992-111792		19920430		
	JP 1992-35435		19920221		
	US 1992-927205		19920807		
	US 1994-231449		19940420		
OS	MARPAT 119:203860				
IT	150209-99-7P				
	RL: SPN (Synthetic preparation); PREP (Preparation)				
	(prepn. of, as endothelin and neurokinin antagonist)				
RN	150209-99-7 CAPLUS				
CN	Cyclo(D-.alpha.-aspartyl-L-tryptophyl-L-leucyl-D-leucyl-L-leucyl-D-tryptophyl) (9CI) (CA INDEX NAME)				



L37 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1987:100588 CAPLUS
 DN 106:100588
 TI Inhibition of phosphorylcholine binding to antibodies using synthetic peptides
 AU Lai, Eric H. C.; Kabat, Elvin A.; Meienhofer, Johannes; Heimer, E. P.; Olson, Arthur J.; Lerner, Richard
 CS Coll. Physicians Surg., Columbia Univ., New York, NY, 10032, USA
 SO Nature (London) (1987), 325(7000), 168-71
 CODEN: NATUAS; ISSN: 0028-0836
 DT Journal
 LA English
 IT **107041-06-5**
 RL: BIOL (Biological study)
 (phosphorylcholine binding to antibodies inhibition by)
 RN 107041-06-5 CAPLUS
 CN L-Valine, N-[N-[N-(N-L-phenylalanyl-L-tyrosyl)-L-methionyl]-L-.alpha.-glutamyl]-L-tryptophyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L37 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1979:104342 CAPLUS
 DN 90:104342
 TI Antibacterial peptide derivatives. Part III. Synthesis of new 3-hydroxyacyl heptapeptides of potential tuberculostatic activity
 AU Neugebauer, Witold; Lamnek, Bernard; Perkowska, Danuta; Kupryszewski, Gotfryd
 CS Inst. Chem., Univ. Gdansk, Gdansk, Pol.
 SO Pol. J. Chem. (1978), 52(7-8), 1435-45

CODEN: PJCHDQ
 DT Journal
 LA English
 IT 66544-14-7P 68838-98-2P 68839-04-3P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and partial deblocking of)
 RN 66544-14-7 CAPLUS
 CN D-Leucine, N-[N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

— Bu-i



RN 68838-98-2 CAPLUS
 CN L-Leucine, N-[N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 68839-04-3 CAPLUS

CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-D-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 68838-99-3P 68839-05-4P 68839-06-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and peptide coupling of, with glutamic acid deriv.)

RN 68838-99-3 CAPLUS

CN D-Leucine,


N-[N-[N-(N-D-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 68839-05-4 CAPLUS
 CN D-Leucine,
 N-[N-[N-[N-(N-L-leucyl-D-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, bis(phenylmethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 68839-06-5 CAPLUS
 CN D-Leucine,
 N-[N-[N-[N-(N-L-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl


L37 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2001 ACS
 AN 1978:406543 CAPLUS
 DN 89:6543
 TI Tuberculostatic 3-hydroxyacyl heptapeptides
 AU Kupryszewski, Gotfryd; Lammek, Bernard; Neugebauer, Witold
 CS Inst. Chem., Univ. Gdansk, Gdansk, Pol.
 SO Pept., Proc. Am. Pept. Symp., 5th (1977), 218-20. Editor(s): Goodman, Murray; Meienhofer, Johannes. Publisher: Wiley, New York, N. Y.
 CODEN: 37OBAT
 DT Conference
 LA English
 IT **66544-14-7P 66544-31-8P 66544-32-9P**
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and deblocking of)
 RN 66544-14-7 CAPLUS
 CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-L-leucyl]-L-valyl]-L- α -aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



—Bu-i




RN 66544-31-8 CAPLUS

CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-D-leucyl]-L-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—Bu-i




RN 66544-32-9 CAPLUS

CN D-Leucine, N-[N-[N-[N-[N-[(1,1-dimethylethoxy)carbonyl]-L-leucyl]-D-leucyl]-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



— Bu-i



IT 66544-15-8P 66544-33-0P 66544-34-1P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. and reaction of, with hydroxyacylglutamic acid deriv.)

RN 66544-15-8 CAPLUS

CN D-Leucine,

N-[N-[N-[N-(L-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-D-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 66544-33-0 CAPLUS

CN D-Leucine,

N-[N-[N-[N-(D-leucyl-L-leucyl)-L-valyl]-L-.alpha.-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA

INDEX NAME)

Absolute stereochemistry.




RN 66544-34-1 CAPLUS

CN D-Leucine,


N-[N-[N-[N-(L-leucyl-D-leucyl)-L-valyl]-L-alpha-aspartyl]-L-leucyl]-, 1-[(4-nitrophenyl)methyl] 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 1 OF 5 USPATFULL
 AN 2000:54077 USPATFULL
 TI Peptide
 IN Manolios, Nicholas, Kensington, Australia
 PA Northern Sydney Area Health Service of Pacific Highway, St. Leonards,
 Australia (non-U.S. corporation)
 PI US 6057294 20000502
 WO 9622306 19960725
 AI US 1997-875013 19970915 (8)
 WO 1996-AU18 19960116
 19970915 PCT 371 date
 19970915 PCT 102(e) date
 PRAI AU 1995-950589 19950116
 AU 1995-950590 19950116
 DT Utility
 EXNAM Primary Examiner: Jones, Dwayne C.; Assistant Examiner:
 Delacroix-Muirheid, C.
 LREP Needle & Rosenberg, P.C.
 CLMN Number of Claims: 12
 ECL Exemplary Claim: 1
 DRWN 2 Drawing Figure(s); 2 Drawing Page(s)
 LN.CNT 1054
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 IT **180994-66-5P**
 (peptides which effect T-cells for treatment of inflammatory or
 autoimmune diseases)
 RN 180994-66-5 USPATFULL
 CN L-Leucine, L-methionylglycyl-L-leucyl-L-arginyl-L-isoleucyl-L-leucyl-L-
 leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L16 ANSWER 136 OF 164 CAPLUS COPYRIGHT 2001 ACS

AN 1995:858555 CAPLUS

DN 124:30418

TI Peptide capable of inducing immune response against HIV and AIDS
preventive or remedy containing the peptide

IN Takiguchi, Masafumi; Miwa, Kiyoshi

PA Ajinomoto Co., Inc., Japan

SO PCT Int. Appl., 59 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9511255	A1	19950427	WO 1994-JP1756	19941019
	W: AU, CA, CN, JP, KR, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	CA 2173138	AA	19950427	CA 1994-2173138	19941019
	AU 9479487	A1	19950508	AU 1994-79487	19941019
	AU 685521	B2	19980122		
	EP 728764	A1	19960828	EP 1994-930335	19941019
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
SE	CN 1133597	A	19961016	CN 1994-193851	19941019
	CN 1055701	B	20000823		
	US 5756666	A	19980526	US 1996-615181	19960404
PRAI	JP 1993-261302	A	19931019		
	WO 1994-JP1756	W	19941019		
AB	This invention relates to (1) a peptide which is a fragment of the whole protein of HIV, the fragment having a sequence of 8 to 11 consecutive amino acid residues, corresponds to an human leukocyte antigen (HLA)-binding motif, is in fact bound to HLA, and can induce a killer cell that targets HIV-infected cells, (2) DNA which codes said peptide, (3) a method for sampling said peptide which involves (a) synthesis of peptides contg. a sequence of 8 to 11 consecutive amino acid residues (fragments of the whole protein of HIV) and corresponding to an HLA-binding motif, (b) selecting peptides actually binding to HLA among these synthetic peptides, and (c) further sampling peptides binding to a HLA class I antigen for stimulating a peripheral lymphocyte of a HIV-diseased patient and inducing a killer cell that specifically targets HIV-infected cells, and (4) an AIDS preventive or remedy contg. said peptide. This peptide induces cell-mediated immunity against HIV. Thus, 58 peptides matching the motif of HLA-B* 3501-binding autoantigen peptide were selected from whole protein sequence of ARV-2 HIV, synthesized by a Shimazu peptide synthesizer, and subjected to the binding test using genetically engineered RMA-S-B* 3501 cells that expresses HLA-B* 3501 antigen. Among these peptides, 26 peptides showed high, medium, and low binding affinity to HLA-B* 3501 antigen. For example, HIV(B35)-3 (nef 133-139) TPGPGIRY, HIV(B35)-14 NPDIVIYQY (I), and HIV(B35)ARV2-8 FPVRPQVPL (II) showed high binding affinity, while HIV(B35)-16 (pol 574-582) TPPLVKLWY (III), HIV(B35)-18 (pol 577-596) EPIVGAETFY (IV), and HIV(B35)POL-20 (pol 311-319) SPAIFQSSM (V) had medium binding affinity. In an assay using genetically engineered T2-B* 3501 cells contg. HLA-B* genes as the target cells, 13 of 26 HLA-B* 3501-binding peptides, including I - IV, were				

effective for inducing cytotoxic **T-cells** from lymphocytes of HIV-infected patients having cytotoxic **T cell-inducing** HLA-B* 3501. Cytotoxic **T cell**-inducing peptides of whole protein sequences of MN, NDK, HXB-2, and SF-2 HIV were similarly obtained.

ST peptide prepn immunity HIV; human leukocyte antigen binding motif; killer cell; target HIV infected cell; AIDS **treatment** peptide; whole protein fragment HIV

IT 111364-12-6P 135861-46-0P 153045-53-5P 157896-38-3P 165898-55-5P
 169034-14-4P 169034-17-7P 169034-19-9P 169034-20-2P 169034-21-3P
 169034-68-8P 169034-69-9P 169034-70-2P 169034-71-3P 169034-72-4P
 169034-73-5P 169034-74-6P 169034-75-7P 169034-76-8P 169034-77-9P
 169034-78-0P 169034-79-1P 169034-80-4P 169034-81-5P 169034-82-6P
 169034-83-7P 169034-84-8P 169034-85-9P 169034-86-0P 169034-87-1P
169034-88-2P 169034-89-3P

RL: BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(prepn. of HIV whole protein-related peptides and binding affinity to human leukocyte antigen)

IT 135993-84-9P 169033-88-9P **169033-89-0P** 169033-90-3P
 169033-91-4P 169033-92-5P 169033-93-6P 169033-94-7P 169033-95-8P
 169033-96-9P 169033-97-0P 169033-98-1P 169033-99-2P 169034-00-8P
 169034-01-9P 169034-02-0P 169034-03-1P 169034-04-2P
169034-05-3P 169034-06-4P 169034-07-5P 169034-08-6P
 169034-09-7P 169034-10-0P **169034-11-1P** 169034-12-2P
 169034-13-3P 169034-14-4P 169034-15-5P 169034-16-6P 169034-17-7P
 169034-18-8P 169034-19-9P 169034-20-2P 169034-21-3P 169034-22-4P
 169034-23-5P 169034-24-6P **169034-25-7P** 169034-26-8P
 169034-27-9P 169034-28-0P 169034-29-1P 169034-30-4P 169034-31-5P
 169034-32-6P 169034-33-7P 169034-34-8P 169034-35-9P 169034-36-0P
 169034-37-1P 169034-38-2P 169034-39-3P 169034-40-6P 169034-41-7P
 169034-42-8P 169034-43-9P 169034-44-0P 169034-45-1P 169034-46-2P
 169034-47-3P 169034-48-4P 169034-49-5P 169034-50-8P 169034-51-9P
 169034-52-0P 169034-53-1P 169034-54-2P 169034-55-3P 169034-56-4P
 169034-57-5P 169034-58-6P 169034-59-7P 169034-60-0P 169034-61-1P
 169034-62-2P 169034-63-3P 169034-64-4P 169034-65-5P
169034-66-6P 169034-67-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of HIV whole protein-related peptides for inducing cell-mediated immune response against HIV and AIDS preventive or remedy)

IT **169034-88-2P**



RL: BPR (Biological process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)

(prepn. of HIV whole protein-related peptides and binding affinity to human leukocyte antigen)

RN 169034-88-2 CAPLUS

CN L-Phenylalanine, N-[N-[N-[N-[N-[N-(1-L-.alpha.-aspartyl-L-prolyl)-L-.alpha.-glutamyl]-L-isoleucyl]-L-valyl]-L-methionyl]-L-histidyl]-L-seryl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 169033-89-0P 169034-05-3P 169034-11-1P

169034-25-7P 169034-66-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(prepn. of HIV whole protein-related peptides for inducing cell-mediated immune response against HIV and AIDS preventive or remedy)


RN 169033-89-0 CAPLUS

CN L-Tyrosine,

L-asparaginyl-L-prolyl-L-.alpha.-aspartyl-L-isoleucyl-L-valyl-L-isoleucyl-L-tyrosyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 169034-05-3 CAPLUS

CN L-Tyrosine, N-[N-[N-[N-[N-(1-L-.alpha.-glutamyl-L-prolyl)-L-valyl]-L-histidyl]-L-.alpha.-glutamyl]-L-valyl]-L-tyrosyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 169034-11-1 CAPLUS

CN L-Leucine,

L-.alpha.-aspartyl-L-prolyl-L-asparaginyl-L-prolyl-L-glutaminyll-L-.alpha.-glutamyl-L-valyl-L-valyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 169034-25-7 CAPLUS

CN L-Isoleucine, N-[N-[N-[N-[N-[N-(1-L-isoleucyl-L-prolyl)-L-threonyl]-L-seryl]glycyl]-L-.alpha.-aspartyl]-L-valyl]-L-valyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.







RN 169034-66-6 CAPLUS
 CN L-Tyrosine,
 L-asparaginyll-L-prolyl-L-.alpha.-glutamyl-L-isoleucyl-L-valyl-
 L-isoleucyl-L-tyrosyl-L-glutaminyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L17 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2001 ACS
 RN 169034-25-7 REGISTRY
 CN L-Isoleucine, N-[N-[N-[N-[N-[N-(1-L-isoleucyl-L-prolyl)-L-threonyl]-L-seryl]glycyl]-L-.alpha.-aspartyl]-L-valyl]-L-valyl]- (9CI) (CA INDEX NAME)
 FS PROTEIN SEQUENCE; STEREOSEARCH
 SQL 9

 SEQ 1 IPTSGDVVI
 MF C40 H69 N9 O14
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.




1 REFERENCES IN FILE CA (1967 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1967 TO DATE)


L11 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2002 ACS
AN 1994:52437 CAPLUS
DN 120:52437
TI Natural peptide ligand motifs of two HLA molecules associated with
myasthenia gravis
AU Malcherek, Georg; Falk, Kirsten; Roetzschke, Olaf; Rammensee, Hans Georg;
Stevanovic, Stefan; Gnau, Volker; Jung, Juenther; Melms, Arthur
CS Neurol. Klin, Univ. Tuebingen, Tuebingen, Germany
SO Int. Immunol. (1993), 5 1229-37
CODEN: INIMEN; ISSN: 0953-8178
DT Journal
LA English

L15 ANSWER 77 OF 88 CAPLUS COPYRIGHT 2002 ACS
AN 1994:577174 CAPLUS
DN 121:177174
TI Naturally processed viral peptides recognized by cytotoxic T lymphocytes
on cells chronically infected by human immunodeficiency virus type 1
AU Tsomides, Theodore J.; Aldovini, Anna; Johnson, R. Paul; Walker, Bruce D.;
Young, Richard A.; Eisen, Herman N.
CS Cent. Cancer Res., Massachusetts Inst. Technol., Cambridge, MA, 02139, USA
SO J. Exp. Med. (1994), 180(4), 1283-93
CODEN: JEMEAV; ISSN: 0022-1007
DT Journal
LA English
IT **139079-41-7**
RL: BIOL (Biological study)
(of reverse transcriptase of HIV-1 virus, as naturally processed
epitope for cytotoxic T-cells)





PAGE 2-A



PAGE 2-B



IT 137715-47-0 137732-20-8

RL: BIOL (Biological study)

myasthenia gravis **treatment** with pharmaceutical compns.
contg.)

RN 137715-47-0 CAPLUS


CN L-Valine,

L-leucyl-L-leucyl-L-valyl-L-isoleucyl-L-valyl-L-.alpha.-glutamyl-


L-leucyl-L-isoleucyl-L-prolyl-L-seryl-L-threonyl-L-seryl-L-seryl-L-alanyl-


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





CO₂H

RN 137732-20-8 CABLUS


CN L-Valine, L-valyl-L-isoleucyl-L-valyl-L- α -glutamyl-L-leucyl-L-isoleucyl-L-prolyl-L-seryl-L-threonyl-L-seryl-L-seryl-L-alanyl- (9CI)



(CA

INDEX NAME)

VIV (α E) L 1 P S T S S A V

Absolute stereochemistry.





L16 ANSWER 139 OF 164 CAPLUS COPYRIGHT 2001 ACS

AN 1995:314564 CAPLUS

DN 122:103468

TI Identification of potential CTL epitopes of tumor-associated antigen
MAGE-1 for five common HLA-A alleles

AU Celis, Esteban; Fikes, John; Wentworth, Peggy; Sidney, John; Southwood,
Scott; Maewal, Ajesh; Del Guercio, Marie-France; Sette, Alessandro;
Livingston, Brian

CS Cytel Corporation, San Diego, CA, 92121, USA

SO Mol. Immunol. (1994), 31(18), 1423-30

CODEN: MOIMD5; ISSN: 0161-5890

DT Journal

LA English

AB Identification of CTL epitopes for tumor-specific responses is important
for the development of immunotherapies to **treat** cancer patients.
We have developed a strategy to identify potential CTL epitopes based on
screening of sequences of target proteins for presence of specific motifs
recognized by the most common HLA-A alleles, and identification of high
affinity binding peptides using in vitro quant. assays. A systematic
anal. using the sequence of the product of the tumor-assocd. MAGE-1 gene
has been carried out. All possible peptides of nine and ten residues,
contg. binding motifs for HLA-A1, -A2.1, A-3.2, -A11 and -A24 were
synthesized and tested for binding using a quant. assay. Out of 237
possible peptide/MHC combinations, 47 cases demonstrated good binding
affinity (Kd .ltoreq. 500 nM). Several peptides were identified as good
MHC binders for each one of the five HLA-A alleles studied (five for
HLA-A1, 11 for HLA-A2.1, 10 for HLA-A3.2, 16 for HLA-A11 and five for
HLA-A24). Furthermore, eight of these peptides were found to bind well

to

more than one HLA-A allele. These results have important implications

for

the development of immunotherapeutic vaccines to **treat** malignant
melanoma.

IT Lymphocyte

(**T-cell**, cytotoxic, potential melanoma-specific CTL

epitopes of tumor-assocd. antigen MAGE-1 for five common HLA-A

alleles)

IT 144449-86-5P 154652-80-9P 160213-09-2P 160213-10-5P 160213-11-6P
160213-14-9P 160213-16-1P 160213-26-3P 160213-27-4P
160213-29-6P **160213-30-9P** 160213-31-0P 160213-32-1P
160215-85-0P 160567-27-1P 160567-28-2P 160567-29-3P 160567-30-6P
160567-31-7P 160567-32-8P **160567-33-9P** 160567-34-0P
160567-35-1P 160567-36-2P 160567-37-3P 160567-38-4P 160567-39-5P
160567-40-8P 160567-41-9P 160567-42-0P 160567-43-1P 160567-44-2P
160567-45-3P 160567-46-4P 160567-47-5P 160567-48-6P 160567-49-7P
160567-50-0P 160567-51-1P **160567-52-2P** 160567-53-3P
160567-54-4P 160567-55-5P 160567-56-6P 160567-57-7P 160567-58-8P
160567-59-9P 160567-60-2P 160567-61-3P 160567-62-4P
160567-63-5P 160567-64-6P 160567-65-7P 160567-66-8P
160567-67-9P 160567-68-0P **160567-69-1P** 160567-70-4P
160567-71-5P **160567-72-6P** 160567-73-7P

RL: BAC (Biological activity or effector, except adverse); PRP

(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL

(Biological study); PREP (Preparation); USES (Uses)

(potential melanoma-specific CTL epitopes of tumor-assocd. antigen
MAGE-1 for five common HLA-A alleles)

IT **160213-14-9P 160213-30-9P 160567-33-9P**
160567-52-2P 160567-59-9P 160567-67-9P

160567-69-1P 160567-72-6P

RL: BAC (Biological activity or effector, except adverse); PRP
(Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL
(Biological study); PREP (Preparation); USES (Uses)
(potential melanoma-specific CTL epitopes of tumor-assocd. antigen
MAGE-1 for five common HLA-A alleles)


RN 160213-14-9 CAPLUS

CN L-Leucine,


N-[N-[N-[N-[N-[N-(N-L-lysyl-L-valyl)-L-alanyl]-L-.alpha.-
aspartyl]-L-leucyl]-L-valyl]glycyl]-L-phenylalanyl]-L-leucyl]- (9CI) (CA
INDEX NAME)


Absolute stereochemistry.

PAGE 1-A



PAGE 1-B






RN 160213-30-9 CAPLUS

```

CN      L-Valine, N-[N2-[N-[N-[N-[N-(N-L-lysyl-L-valyl)-L-leucyl]-L-.alpha.-
      glutamyl]-L-tyrosyl]-L-valyl]-L-isoleucyl]-L-lysyl]- (9CI)  (CA INDEX
      NAME)

```



Absolute stereochemistry.



RN 160567-33-9 CAPLUS

CN L-Lysine, L-alanyl-L-.alpha.-aspartyl-L-leucyl-L-valylglycyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160567-52-2 CAPLUS

CN L-Isoleucine,

L-seryl-L-tyrosyl-L-valyl-L-lysyl-L-valyl-L-leucyl-L-.alpha.-
glutamyl-L-tyrosyl-L-valyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






RN 160567-59-9 CAPLUS

CN L-Leucine,

N-[N-[N-[N-[N-[N-(N-L-valyl-L-alanyl)-L-.alpha.-aspartyl]-L-leucyl]-L-valyl]glycyl]-L-phenylalanyl]-L-leucyl]- (9CI) (CA INDEX NAME)



Absolute stereochemistry.



RN 160567-67-9 CAPLUS

CN L-Tyrosine, N-[N2-[N-[N-[N-[N-[N-(N-L-.alpha.-aspartyl-L-leucyl)-L-valyl]glycyl]-L-phenylalanyl]-L-leucyl]-L-leucyl]-L-leucyl]-L-lysyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 160567-69-1 CAPLUS

CN L-Lysine, L-.alpha.-aspartyl-L-leucyl-L-valylglycyl-L-phenylalanyl-L-leucyl-L-leucyl-L-leucyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 160567-72-6 CAPLUS

CN L-Lysine,


N2-[N-[N-[N-[N-[N-[N2-(N-L-tyrosyl-L-valyl)-L-lysyl]-L-valyl]-L-leucyl]-L-.alpha.-glutamyl]-L-tyrosyl]-L-valyl]-L-isoleucyl]- (9CI)

(CA

INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

